Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2007

View Archived Issues

Fourth quarter highlights at Schering-Plough

Snapshots of studies from the International Neuropsychological Society meeting

Roche introduces new R&D operating model

Volunteers selected for clinical trial of Generex's synthetic avian influenza vaccine

New therapeutic agents for hepatitis C virus (HCV) infection reported in recent Gilead patent

Recent Aditech patent announces novel antipsoriatic agents

Recent patents disclose new antidepressive, antipsychotic and anxiolytic agents

Studies of dermatologic agents from Barrier presented at AAD conference

Enrollment completed in safety study of EOquin in noninvasive bladder cancer

CHK1 drug discovery program advances

Ranbaxy and GSK sign new R&D agreement

Forest and Replidyne terminate faropenem collaboration

Allon Therapeutics outlines recent progress and upcoming milestones

CytRx to determine maximum dose of arimoclomol

Recordati and Meda sign German sales agreement for Zaniril

CD24 and BAG-1 suggested as prognostic markers for aggressive breast cancer

Pola describes novel topical antinflammatory agents

Lumiliximab begins registration study in CLL

Financing at Proacta to support development of PR-104

Amgen warns medical community on off-label use of Aranesp

Extended-release QuitPak begins pilot study for smoking cessation

SCOLR Pharma reports outcomes for CDT-based therapies

Celtic Pharma halts study of TransMID for glioblastoma multiforme

ABT-737 shows antimyeloma activity alone or in combination in preclinical studies

Tibotec begins phase I study with HCV protease inhibitor

Daiichi Sankyo returns KAI-9803 development rights to KAI

SRI and Telik sign agreement for C-243

BioProgress to inlicense MuGard

Kogenate Bayer approved for continuous infusion in hemophilia A

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...